Treatment and prophylaxis of hematological side effects of chronic hepatitis C antiviral therapy
Abstract
The aim of review. To characterize advantage of application of a leukocytic interferon a (IFN-a) for prophylaxis of cytopenia at antiviral therapy of chronic hepatitis C (CHC).
Original positions. Hematological undesirable effects of antiviral agents represent the most serious complication of etiological treatment of CHC. Thus development of neutropenia and thrombocytopenia is related first of all to application of IFN-a. The basic approach to cope with hematological complications includes prescription of hemopoietic factors at already developed cytopenia. Possible delay of correcting preparation action and increase of the total treatment cost is disadvantage of this approach. Choice of the most safe medicine that is justified, first of all, at patients with initially present cytopenias or having those at previous courses of antiviral therapy may be an alternative. It is possible to offer leukocytic IFN-a «Alfaferone» As such a drug, which efficacy, at least in CHC patients with non-1-st genotype, is not lower, and even is higher, than that of recombinant analogues. At prescription of leukocytic IFN-a necessity in hemopoietic factors maintenance therapy develops rather rarely, in which case significantly lower doses and duration of treatment is required.
Conclusion. Application of leukocytic IFN-a within antiviral therapy of CHC is characterized by high efficacy and safety that allows to recommend it as a drug of choice at «difficult» categories of patients.
About the Author
A. O. Buyeverov
Московская медицинская академия им. И.М. Сеченова
Russian Federation
Russian Federation
References
1. Бурневич Э.З. Коррекция и профилактика гематологических нежелательных явлений при противовирусной терапии хронического гепатита С // Гепатологический форум. – 2006. – № 2. – С. 15–22.
2. Никитин И.Г., Гогова Л.М., Байкова И.Е. и др. Человеческий лейкоцитарный альфа-интерферон в комбинированной терапии больных хроническим гепатитом С, инфицированных не 1-м генотипом вируса // Клин. перспект. гастроэнтерол. гепатол. – 2009. – № 1. – С. 33–37.
3. American Gastroenterological Association technical review on the management of hepatitis C // Gastroenterology. – 2006. – Vol. 130. – P. 231–264.
4. Barbaro G., Grisorio B., Fruttaldo L. et al. Good safety profile and efficacy of leucocyte interferon-a in combination with oral ribavirin in treatment-naive patients with chronic hepatitis C // Biodrugs. – 2003. – Vol. 17. – P. 433–439.
5. Bargiggia S., Thorburn D., Anderloni A. et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study // Aliment. Pharmacol. Ther. – 2005. – Vol. 22. – P. 209–215.
6. Benci A., Caremani M., Tacconi D. et al. Trombocytopenia in patients with HCV-positive chronic hepatitis: efficacy of leucocyte interferon-a treatment // Int. J. Clin. Pract. – 2003. – Vol. 57. – P. 17–19.
7. Casato M., Antonelli G., Maggi F. et al. Resistance to recombinant alpha interferon therapy in idiopathic mixed crioglobulinemia: reduction of remission by natural alpha interferon both in antibody-positive and negative patients // J. Biol. Regul. Homeost. Agents. – 1994. – Vol. 8. – P. 56–59.
8. Colombatto P., Oliveri F., Leandro G. et al. Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis // Ital. J. Gastroenterol. Hepatol. – 1997. – Vol. 29. – P. 441–447.
9. Farmer D. et al. Filgrastim for the neutropenia associated with combination therapy in chronic hepatitis C // Gastroenterology. – 2005. – Vol. 128 (suppl. 2). – P. 1583.
10. Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection // N. Engl. J. Med. – 2002. – Vol. 347. – P. 975–982.
11. Janczewska-Kazek E., Pisula A., Kukla M. et al. Therapy with natural leucocyte interferon and ribavirin in «difficult to treat» patients infected with HCV // Exp. Clin. Hepatol. – 2006. – Vol. 2. – P. 31–35.
12. Koirala J., Gandotra S.D., Rao S. et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy // J. Viral Hepat. – 2007. – Vol. 14. – P. 782–787.
13. Manns M.P., McHutchinson J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial // Lancet. – 2001. – Vol. 358. – P. 958–965.
14. McHutchinson J.G., Afdal N., Shiffman M.L. et al. Efficacy and safety of eltrombopag, an oral platelet growth factor, in subjects with HCV associated thrombocytopenia: preliminary results from a phase II dose-ranging study // J. Hepatol. – 2006. – Vol. 44 (suppl. 2). – P. 745.
15. Porubcin S., Schrйter I., Kristian P., Pellovб A. Haematologic adverse effects of treatment of chronic viral hepatitis B and C // Klin. Mikrobiol. Infekc. Lek. – 2008. – Vol. 14. – P. 74–78.
16. Santantonio T., Milella M., Antonelli G., Scagnolari C. Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon // J. Hepatol. – 2006. – Vol. 45. – P. 758–761.
17. Soza A., Everhart J.E., Ghany M.G. et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C // Hepatology. – 2002. – Vol. 36. – P. 1273–1279.
18. Stravitz R.T., Chung H., Sterling R.K. et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C // Am. J. Gastroenterol. – 2005. – Vol. 100. – P. 1415–1419.
19. Sulkowski M.S. Management of the hematologic complications of hepatitis C therapy // Clin. Liver Dis. – 2005. – Vol. 9. – P. 601–616.
20. Toccaceli F., Rosati S., Scuderi M. et al. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment // Hepatogastroenterology. – 1998. – Vol. 45. – P. 1748–1752.
Review
For citations:
Buyeverov A.O. Treatment and prophylaxis of hematological side effects of chronic hepatitis C antiviral therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2009;19(3):76-81. (In Russ.)
Views:
14
Email this article 
